Effects of chronic 5'-([(Z)-4-amino-2-butenyl]methylamino)-5'-deoxy- adenosine (AbeAdo) treatment on polyamine and eIF-5A metabolism in AbeAdo-sensitive and -resistant L1210 murine leukaemia cells.
We have previously reported that prolonged chronic exposure to the S-adenosyl-L-methionine decarboxylase (AdoMetDC) inhibitor, 5'-([(Z)-4-amino-2-butenyl]methylamino)-5'-deoxy-adenosine (MDL 73811, AbeAdo), leads to cytostasis of L1210 cells [Byers, Ganem and Pegg (1992) Biochem. J. 287, 717-724]. Further studies to investigate the mechanism by which these effects are brought about were carried out by comparing an L1210-derived cell line (R20) that is resistant to AbeAdo with the parent cells. The R20 cells were derived by two rounds of AbeAdo-induced cytostasis followed by rescue with exogenous polyamines. Cytostasis was induced in L1210 cells treated for 12 days with 10 microM AbeAdo; however, exposure to up to 40 microM AbeAdo did not induce cytostasis in R20 cells. Putrescine levels were elevated and spermine levels were depleted in both treated L1210 and treated R20 cells. Spermidine was depleted in treated L1210 cells but was only partly reduced in treated R20 cells. AdoMetDC activity was below the limit of detection in treated L1210 cells but, although greatly reduced, could be measured in the treated R20 cells. The resistance of the R20 cells to the effects of AbeAdo on cell growth and spermidine depletion correlated with reduced AbeAdo accumulation by R20 cells. In the absence of spermidine synthesis, unhypusinated eukaryotic translation initiation factor 5A (eIF-5A) accumulated in AbeAdo-treated L1210 cells. There was no detectable accumulation of unhypusinated eIF-5A in R20 cells. Unhypusinated eIF-5A accumulated during AbeAdo treatment was depleted in L1210 cells rescued by exogenous spermidine. These findings are consistent with the hypothesis that AbeAdo-induced cytostasis is due to the loss of hypusinated eIF-5A. However, spermine was able to rescue AbeAdo-treated L1210 cells without significantly reducing the unhypusinated eIF-5A accumulated during AbeAdo treatment, suggesting that only a small amount of the unmodified protein must be hypusinated to restore cell growth.
Byers
T L
TL
Department of Cellular and Molecular Physiology, M. S. Hershey Medical Center, Hershey, PA 17033.
Wiest
L
L
Wechter
R S
RS
Pegg
A E
AE
D012437:Adenosylmethionine Decarboxylase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000818:Animals; D002455:Cell Division / Q000187:drug effects; D003839:Deoxyadenosines / Q000008:administration & dosage / Q000494:pharmacology*; D004351:Drug Resistance; D007939:Leukemia L1210 / Q000378:metabolism*; D051379:Mice; D010448:Peptide Initiation Factors / Q000378:metabolism*; D011073:Polyamines / Q000378:metabolism*; D016601:RNA-Binding Proteins; D012436:S-Adenosylmethionine / Q000378:metabolism; D013095:Spermidine / Q000378:metabolism / Q000494:pharmacology; D013096:Spermine / Q000378:metabolism / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D000097574:Eukaryotic Translation Initiation Factor 5A
D012437:Adenosylmethionine Decarboxylase; D003839:Deoxyadenosines; D010448:Peptide Initiation Factors; D011073:Polyamines; D016601:RNA-Binding Proteins; D012436:S-Adenosylmethionine; D013095:Spermidine; D013096:Spermine; D000097574:Eukaryotic Translation Initiation Factor 5A; C065859:MDL 73811